– CD20-targeted GADLEN demonstrated preclinical proof of concept of rapid B cell depletion in humanized mice and non-human primates, intended for...
Providence, RI, March 16, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a next generation biopharma company, announces initiation...
--Interrogation of circulating tumor cells (CTCs) shows downregulation of KEAP1 gene promotes resistance to immune checkpoint blockade in melanoma-- --Study provides...
NORCROSS, Ga., March 16, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3,...
DOYLESTOWN, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused...
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that...
FLORHAM PARK, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a...
INB-300, a gamma-delta T cell based chimeric antigen receptor (CAR) platform, demonstrated the ability to target malignant cells while preserving...
FORT LEE, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating...
- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas underway - - Ended 2022 with cash,...
Initial data expected in the second half of 2023 WARMINSTER, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation...
Milestone marks transition of Pyxis Oncology to a clinical-stage company Preliminary data anticipated in early 2024 CAMBRIDGE, Mass., March 16,...
Phase 1/2 clinical trial evaluating MRT-2359 for treatment of MYC-driven solid tumors ongoingDisclosure of initial data from Phase 1 arm...
WATERTOWN, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical...
Company Expects to Achieve Several Near-Term Clinical MilestonesHOUSTON, March 16, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology...
Results from Planned Interim Analysis Expected Fourth Quarter 2023 Approximately 21 Million Adults in U.S. Suffer From a Major Depressive...
– Company expecting Investigational New Drug (IND) clearance in the first half of 2023 for CABA-201, a 4-1BB-containing fully human...
– Clinical update of allo-iNKT cells (agenT-797) alone or in combination with approved anti-PD-1 in advanced solid tumors NEW YORK,...
Louvain-la-Neuve, Belgium, 14 March 2023 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology wants...
New Business Strategy Focused on Precision OncologyLONDON and HONG KONG, March 14, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:...